Gufic Biosciences Limited
391.80
INR
-2.20
(-0.56%)
ISIN
INE742B01025
Return %
Stock
S&P 500
1Y
13.78
13.14
3Y
55.26
80.78
5Y
112.76
67.74
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Pranav Jayesh Choksi
- Full Time Employees
- 2,903
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- SM House Mumbai MA India 400057
- IPO Date
- Oct 19, 2004
- Website
- gufic.com
- Similar Companies
- Business
- Gufic Biosciences Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), herbal formulations, and consumer personal care products. Its core products include lyophilized injections across therapeutic segments such as antibiotics, antifungals, cardiac medicines, infertility treatments, antivirals, proton pump inhibitors, critical care medicines, and nutraceuticals. The company produces pharmaceutical formulations in various dosage forms including injectables, syrups, ointments, lotions, tablets, capsules, and herbal products, serving over 15 therapeutic areas with a portfolio of more than 100 products and 200 stock-keeping units (SKUs). Gufic Biosciences is one of the largest manufacturers of lyophilized injections in India and operates a fully automated robotic-armed lyophilization plant. It also manufactures consumer personal care items such as sanitary napkins and anti-stretch mark creams. The company has a research and development pipeline focused on complex injectables, biologicals, immuno-oncology, assisted reproductive technology therapies, toxins, and science-based nutraceuticals. Founded in 1970 and headquartered in Mumbai, India, Gufic Biosciences has expanded its operations internationally, with subsidiaries including Gufic Ireland Limited and a presence in countries like Australia, Mexico, South Africa, the Philippines, Thailand, and Nepal. Recent strategic developments include additional investments in subsidiaries and funding for Gufic Ireland Limited, expansion of the product pipeline with over 50 products under development targeting regulated and semi-regulated markets, and forthcoming approval for Immunocin-Alpha, an innovative immunotherapy for sepsis. The company recently launched new senior management appointments to strengthen its critical care and fertility business units. Gufic continues to focus on expanding its global reach with over 150 products in registration pipelines across more than 30 countries, enhancing its presence in critical care, fertility, nutraceuticals, and aesthetic and derma solutions. Gufic Biosciences maintains a leadership position in specialized medicinal segments by leveraging its innovation in lyophilization technology and a diversified product portfolio spanning pharmaceutical formulations, bulk drugs, and herbal formulations. The company's products are supplied to major hospital chains and medical facilities across India and abroad. Its business segments include domestic branded formulations, contract manufacturing, and exports with a strong emphasis on research and regulatory compliance. The company’s mission centers on making high-quality, cost-effective pharmaceutical products widely accessible while advancing innovation in specialized medical therapies and formulations.